8-K: Kymera Therapeutics Announces Q1 2025 Financial Results and Unveils New IRF5 Degrader Program

Kymera Therapeutics reports its Q1 2025 financial results, highlights pipeline progress, and introduces a new oral IRF5 degrader program, KT-579, for immuno-inflammatory diseases.

Summary

• Kymera Therapeutics announced its first quarter 2025 financial results and provided a business update.
• The company completed the KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial, with data expected in June 2025.
• The first patient was dosed in the KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis, with data expected in Q4 2025.
• Kymera introduced KT-579 (IRF5), a new oral immunology degrader program expected to enter Phase 1 clinical trial in early 2026.
• KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD are ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment in April 2025.
• A strategic decision was made not to advance KT-295 (TYK2) into further clinical development.
• The company is well-capitalized with $775 million in cash as of March 31, 2025, providing an extended runway into the first half of 2028.
• Collaboration revenues were $22.1 million for the first quarter of 2025, compared to $10.3 million for the first quarter of 2024.
• Research and development expenses were $80.3 million for the first quarter of 2025, compared to $48.8 million for the first quarter of 2024.
• Net loss was $65.6 million for the first quarter of 2025, compared to $48.6 million for the first quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the progress in clinical trials, the introduction of a new program, and the extended cash runway. However, the increased net loss and R&D expenses temper the overall sentiment.

Positives

• Kymera is well-capitalized with $775 million in cash, extending the cash runway into the first half of 2028.
• The company achieved a $20 million milestone payment from Sanofi related to the IRAK4 program.
• Collaboration revenues increased significantly in Q1 2025 compared to Q1 2024.
• Kymera is advancing its STAT6 program with Phase 1 data expected in June 2025 and Phase 1b data in Q4 2025.
• The company is expanding its pipeline with the addition of the KT-579 (IRF5) program.
• Kymera appointed Noah Goodman as Chief Business Officer.

Negatives

• Kymera decided not to advance KT-295 (TYK2) into clinical development.
• The net loss increased to $65.6 million for the first quarter of 2025, compared to $48.6 million for the first quarter of 2024.
• Research and development expenses increased to $80.3 million for the first quarter of 2025, compared to $48.8 million for the first quarter of 2024.

Risks

• The success of clinical trials is uncertain, and preliminary results may not be indicative of later trial results.
• The company's ability to obtain regulatory approvals for its drug candidates is not guaranteed.
• The company's financial condition depends on its ability to secure sufficient funding for its operating expenses and capital expenditure requirements.

Future Outlook

Kymera expects its cash and cash equivalents to provide a cash runway into the first half of 2028, beyond multiple clinical inflection points in its pipeline. The company plans to advance KT-579 into Phase 1 clinical testing in early 2026 and initiate Phase 2b studies for KT-621 in AD and asthma patients in late 2025 and early 2026, respectively.

Management Comments

• The Kymera team continues to advance our first-in-class pipeline on the path to revolutionizing the treatment of complex immuno-inflammatory diseases, said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics.
• We are making tremendous progress across our programs and approaching key near term inflection points.
• We are excited to introduce KT-579, our oral IRF5 degrader program.
• This strategic prioritization also extends our runway from mid-2027 into the first half of 2028, well beyond multiple important catalysts across our pipeline.

Industry Context

Kymera is focused on targeted protein degradation (TPD) to develop oral small molecule degrader medicines for immunological diseases, a competitive field with significant unmet needs. The company's approach aims to address disease targets and pathways inaccessible with conventional therapeutics, potentially offering a new generation of convenient and effective therapies.

Comparison to Industry Standards

• Kymera's KT-621 aims to provide dupilumab-like activity in an oral form, potentially offering a more convenient treatment option for Th2 diseases compared to injectable biologics like Dupixent.
• The development of KT-579, an oral IRF5 degrader, targets a historically undrugged transcription factor, potentially offering a novel mechanism of action compared to existing small molecule inhibitors and biologics in rheumatic and autoimmune diseases.
• Kymera's collaboration with Sanofi on KT-474 (IRAK4) is similar to other partnerships in the industry, such as Galapagos and Gilead for filgotinib, where large pharmaceutical companies collaborate with smaller biotech firms to develop and commercialize novel therapies.

Management Changes

Stakeholder Impact

• Shareholders: The extended cash runway and pipeline progress are positive for shareholders.
• Employees: The focus on key programs and the addition of a new program may impact employee roles and responsibilities.
• Patients: The development of new oral therapies has the potential to improve treatment options for patients with immuno-inflammatory diseases.
• Sanofi: The ongoing collaboration with Sanofi on the IRAK4 program continues to be a key partnership for Kymera.

Next Steps

• Kymera will disclose the complete KT-621 Phase 1 healthy volunteer SAD/MAD data in June 2025.
• Kymera plans to present additional KT-621 preclinical data at the American Thoracic Society (ATS) Annual Meeting being held May 16-21, 2025.
• Kymera intends to advance KT-579 into Phase 1 clinical testing in early 2026.
• Sanofi will continue Phase 2b trials for KT-474/SAR444656 in HS and AD, with primary completion expected in the first half of 2026 and mid-2026, respectively.
• Two parallel Phase 2b studies in AD and asthma patients are planned to begin in the fourth quarter of 2025 and first quarter of 2026, respectively.

Key Dates

Keywords

Kymera Therapeutics, STAT6, IRF5, IRAK4, TYK2, protein degradation, immunology, clinical trials, financial results, collaboration, Sanofi, KT-621, KT-579, KT-474, KT-295